This post first appeared as an issue of the a16z Bio Newsletter. Subscribe to stay on top of the latest trends in bio and healthcare.
Right now, accurate and reliable information is absolutely essential. We are maintaining a list of select Coronavirus Resources & Readings, which we use to keep up to date with the latest information, the response, and the global impact. We hope you’ll find it useful too.
As the COVID-19 epidemic continues to spread, so does the strain on the healthcare system. Virtual medicine, aka “telemedicine,” has been slowly gaining traction in recent years with both providers and consumers. But thanks to the novel coronavirus, the demand has skyrocketed overnight. With most of us sheltering in place and aiming to minimize contact between potentially infected individuals, virtual care is now the first stop for many seeking healthcare.
In this podcast, a16z general partners Julie Yoo and Vijay Pande discuss with Hanne Tidnam how virtual medicine gives us an opportunity to rethink and re-engineer how care is delivered. What it is good at, what are the current limitations, what’s changing, what needs to change… and where could it eventually go one day?
If the best way to know whether a medicine is safe and effective is through a randomized controlled trial (RCT) and clinical trials, then where does (and doesn’t) real-world data and real-world evidence (RWE) come in? The topic is especially heated lately given recent concerns and claims around particular drugs in the context of the novel coronavirus pandemic. So in this 16-ish minutes episode and tweetstorm, general partner Vijay Pande breaks down the debate between RWE vs. RCT in conversation with Sonal Chokshi. Is it a tradeoff between speed and safety, or is that a false dichotomy altogether? How has, and could, the role of the FDA and payors evolve here?
In last month’s newsletter, we discussed EPIC’s “letter heard around the healthcare world” opposing the proposed draft rules from the Department of Health and Human Services regarding liquidity, interoperability, and portability in healthcare data. This month, these rules became official. In this episode of our news show 16 Minutes, a16z’s General Partner Julie Yoo and Venkat Mocherla discuss with Sonal Chokshi the content of the rules; what they mean for hospitals—particularly in this critical time in healthcare; the implications for providers and payers; security concerns; and opportunities for startups and incumbents in this space.